Hi, glad to see you on iHub. This place was dead 3 years ago.(see my bold post, #18) IMHO, Geron and the FDA are still dancing around with this hot potato. Geron isn't banging on the door demanding anything openly and they are giving the FDA their due. But I hand it to Okarma that they have their act together not only by using a Bush approved cell line but also developing it without mouse feeder cells. Geron has been working with the FDA from the beginning and as you know, the preclinicals were extensive. Also you know that other stem cell research data is coming from all over the place so the FDA/ NIH are in the midst of it.
To anybody considering: Low 6's is a good buy here. If I were newly interested in GERN I'd fish in this range. Also looking for more at a lower sp with the general world situation weighing in will probably happen(and don't dismiss hijinks from the political FDA). I agree that these Geron guys know what they're doing, so it's a matter of time. The IP is coming to fruition. Accumulation window is shrinking: I expect a bump this November when good interim data is presented at ASH from Geron's oncology trials now underway. The stem cell IND data submittal is supposed to be 1Q 2007.
Market Data 
Markets 
AI
